FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to the preparation of a therapeutic and/or prophylactic agent for use in transplant rejections, immunological diseases, allergic diseases, inflammatory diseases, thrombosis, cancer, etc., is exposed to human Orai1. Present invention relates to a pharmaceutical composition containing an antibody, which specifically recognizes human Orai1 and has T-lymphocyte activation inhibiting activity.
EFFECT: disclosed is an anti-Orai1 antibody.
31 cl, 58 dwg, 1 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COAGULATING FACTOR VIII CO-FACTOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED MOLECULE AS ACTIVE INGREDIENT | 2018 |
|
RU2812909C2 |
| ANTIBODY AGAINST SIRPα | 2019 |
|
RU2791002C2 |
| ANTIBODY TO TIGIT AND ITS USE | 2019 |
|
RU2786434C2 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
| ANTI-IL31 ANTIBODIES FOR VETERINARY USE | 2018 |
|
RU2795485C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| PREDICTION OF RISK OF DEVELOPMENT OF UNDESIRED REACTION RELATED TO ADMINISTRATION OF ANTIBODY TO ALK2 AND CAPABILITY OF RESPONDING TO TREATMENT WITH ANTIBODY TO ALK2 | 2019 |
|
RU2783762C2 |
| DOG ANTIBODIES WITH MODIFIED CH-CH SEQUENCES | 2014 |
|
RU2815059C2 |
